Advancing Scalable, Compliant & Innovative Cell & Gene Therapy Production in the DACH Region

View the 2025 Post-Event Report

Secure Early-Bird Pricing of £699 - Register Your Interest

AGENDA AT A GLANCE

DAY 1	DAY 2
Unlocking Commercial Success in DACH’s Cell & Gene Therapy	Quality Assurance in CGT
Industry Roundtables: What's Next for Bioprocessing in CGT?	Novel Purification & Intensification Strategies
Overcoming Bottlenecks in Viral Vector Manufacturing	Manufacturing Innovations for Allogeneic and In Vivo Therapies
Decentralized Production for Next-Gen Cell & Gene Therapies	Smart Factories: The Role of Digitalization & AI
Drink Reception	End of Conference

As the Cell & Gene Therapy (CGT) industry matures, the DACH region is emerging as a critical hub for commercial manufacturing and global supply.

Yet, the road from clinical promise to large-scale delivery remains paved with technical, regulatory, and supply chain challenges — particularly in viral vector capacity, closed-system adoption, and digital factory readiness.

CGT Manufacturing DACH 2026 will unite leaders from biopharma, biotech, CDMOs, regulators, and technology innovators to exchange practical solutions for scaling production, maintaining quality, and enabling global distribution.

;

Key Themes & Topics

At the heart of CGT Manufacturing DACH, the programme addresses commercial scale-up, manufacturing innovation, and regulatory excellence in advanced therapies:

Industry Roundtables: The Future of CGT Bioprocessing

Interactive discussions with senior leaders on upcoming trends, regional opportunities, and global competitiveness in cell & gene therapy manufacturing.

Overcoming Bottlenecks in Viral Vector Production

Strategies to improve yields, streamline upstream and downstream processes, and manage facility constraints for scalable viral vector supply.

Quality Assurance & Regulatory Compliance in CGT

Addressing GMP, QC, and evolving regulatory requirements for both clinical-stage and commercial-scale manufacturing.

Novel Purification & Intensification Strategies

Exploring next-generation purification platforms, continuous processing, and intensified manufacturing for improved efficiency and throughput.

Manufacturing Innovations for Allogeneic & In Vivo Therapies

Adapting production systems for diverse therapy types, from donor-derived cell therapies to in vivo delivery platforms.

Smart Factories: Digitalization & AI in CGT

Leveraging Digital Twins, automation, and AI to enable predictive, data-driven manufacturing and faster process optimization.

200 max

Senior Attendees

Join the exclusive and focused gathering that unites the DACH region’s cell & gene therapy manufacturing leaders. Connect with senior decision-makers driving the scale-up, compliance, and commercialization of advanced therapies, from viral vector production to allogeneic and in vivo platforms.

30+

Expert Speakers

Gain first-hand insights from industry pioneers on overcoming manufacturing bottlenecks, optimizing closed and automated systems, intensifying production, and ensuring GMP compliance. Learn from real-world case studies shaping the future of CGT manufacturing in DACH and beyond.

20+

Companies Represented

Engage in targeted networking sessions to exchange expertise, discuss regulatory and operational challenges, and explore partnership opportunities with peers, CDMOs, and technology innovators in advanced therapies.

EXPECTED AUDIENCE SNAPSHOT

Attendance from

Biopharma

40%

Attendance from

Big Pharma

50%

Attendance from

Academia

10%

Decision Makers

By Geography

BY PROFILE

European Biopharma & Big Pharma

International Biopharma & Big Pharma

CDMO & CMO

Technology & Service Providers

Academic & Research Institutes

BY JOB TITLE

C-Suite

VP/Director

Division Heads

Senior Scientist

Business Development

Target Attendee Snapshot